search
Back to results

Family-centered HIV Care, Viral Suppression and Retention in HIV-positive Children, Swaziland (FAM-CARE)

Primary Purpose

HIV Infections

Status
Completed
Phase
Not Applicable
Locations
Swaziland
Study Type
Interventional
Intervention
FAM-CARE
Sponsored by
Elizabeth Glaser Pediatric AIDS Foundation
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for HIV Infections

Eligibility Criteria

undefined - 14 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • HIV-positive child aged <15 years receiving HIV care at the study facility.

Exclusion Criteria:

  • At least one family member residing in the household is also HIV-positive and is receiving services at the study facility

Sites / Locations

  • Mbabane

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

FAM-CARE

Control Standard of Care

Arm Description

Two facility "clusters" (one hospital and one health center, with their filter clinics) will be randomized to initiate the FAM-CARE program (where all HIV-positive family members are seen together as a unit and receive care together) with viral load monitoring

Two "clusters" (one hospital and one health center, with their filter clinics) will be control standard-of care (usual practice) sites. Standard HIV care and treatment services, (drug resupply, clinical assessments etc.), including viral load monitoring, will be provided to adults and children in separate adult and pediatric clinics, even though they many be from the same family.

Outcomes

Primary Outcome Measures

Proportion of HIV-positive children on ART virally suppressed
Proportion of HIV-positive children on ART with viral suppression (defined as HIV RNA copies/mL below the level of assay detection) and the proportion with HIV RNA <1,000 copies/mL at 18 months after enrollment
Proportion of HIV-positive on ART virally unsuppressed
Proportion of HIV-positive children on ART with HIV RNA >1000 copies/mL 18 months after enrollment into the study.

Secondary Outcome Measures

Proportion HIV-positive children on ART virally suppressed (<1,000 copies/mL of HIV RNA) at 6 and 12 months after study enrollment
Proportion of HIV-positive children on ART with viral suppression (defined as HIV RNA copies/mL below the level of assay detection) and HIV RNA >1000 copies/mL
Factors associated with HIV viral suppression
Individual and family factors associated with viral suppression.
Loss to follow-up
Loss to follow-up (not seen in clinical care >3 months)
ART initiation
ART initiation in HIV-positive children not on ART at study entry
Acceptability of the FAM-CARE program based on individual interview responses
Acceptability of the FAM-CARE program to caregivers and health care provider as measured from responses on individual interviews using a structured questionnaire

Full Information

First Posted
January 2, 2018
Last Updated
January 27, 2020
Sponsor
Elizabeth Glaser Pediatric AIDS Foundation
Collaborators
United States Agency for International Development (USAID), Ministry of Health, Swaziland
search

1. Study Identification

Unique Protocol Identification Number
NCT03397420
Brief Title
Family-centered HIV Care, Viral Suppression and Retention in HIV-positive Children, Swaziland
Acronym
FAM-CARE
Official Title
Effect of Family-centered Model of HIV Care (FAM-CARE) on Viral Suppression and Retention in Care of HIV-positive Children in Swaziland
Study Type
Interventional

2. Study Status

Record Verification Date
January 2020
Overall Recruitment Status
Completed
Study Start Date
September 13, 2017 (Actual)
Primary Completion Date
October 30, 2018 (Actual)
Study Completion Date
July 30, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Elizabeth Glaser Pediatric AIDS Foundation
Collaborators
United States Agency for International Development (USAID), Ministry of Health, Swaziland

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The study will evaluate the effect of implementing a family-centered care (FAM-CARE) program (where all HIV-positive family members are seen together as a unit and receive care together) on viral suppression and retention in HIV-positive children <15 years through enrollment of a prospective cohort of 660 HIV-positive children and their caregivers at sites that were randomized to either implement the family-care program (intervention sites) or continue the current standard of care (control sites).
Detailed Description
The proposed study will evaluate the effect of implementing a FAM-CARE program on viral suppression and retention in children through enrollment of a prospective cohort of HIV-positive children and their caregivers at sites implementing the FAM-CARE program and control sites continuing the current standard of care. The study will be conducted in four "clusters" of facilities (2 hospitals and 2 health centers and their filter clinics) in the Hhohho region of Swaziland. Two facility "clusters" (one hospital and one health center, with their filter clinics) will be randomized to initiate the FAM-CARE program with viral load monitoring and two "clusters" (one hospital and one health center, with their filter clinics) will be control standard-of care sites. A prospective cohort of HIV-positive children and their caregivers will be followed in the FAM-CARE program sites and control sites. Each child will be followed for 18 months following enrollment. The primary objective is to evaluate the effect of the FAM-CARE program on the rates of viral suppression and retention in care, comparing rates of viral suppression and retention in children enrolled in FAM-CARE versus control sites. The study will also evaluate factors associated with viral suppression and retention (including family demographic characteristics), and conduct qualitative interviews to assess the acceptability of the FAM-CARE program by caregivers and health care providers in the intervention sites.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
HIV Infections

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
742 (Actual)

8. Arms, Groups, and Interventions

Arm Title
FAM-CARE
Arm Type
Experimental
Arm Description
Two facility "clusters" (one hospital and one health center, with their filter clinics) will be randomized to initiate the FAM-CARE program (where all HIV-positive family members are seen together as a unit and receive care together) with viral load monitoring
Arm Title
Control Standard of Care
Arm Type
Active Comparator
Arm Description
Two "clusters" (one hospital and one health center, with their filter clinics) will be control standard-of care (usual practice) sites. Standard HIV care and treatment services, (drug resupply, clinical assessments etc.), including viral load monitoring, will be provided to adults and children in separate adult and pediatric clinics, even though they many be from the same family.
Intervention Type
Other
Intervention Name(s)
FAM-CARE
Intervention Description
Family-centered care, where all HIV-positive family members are seen together as a unit and receive HIV care and treatment services together, for HIV-positive children and their caregivers
Primary Outcome Measure Information:
Title
Proportion of HIV-positive children on ART virally suppressed
Description
Proportion of HIV-positive children on ART with viral suppression (defined as HIV RNA copies/mL below the level of assay detection) and the proportion with HIV RNA <1,000 copies/mL at 18 months after enrollment
Time Frame
18 months after study enrollment.
Title
Proportion of HIV-positive on ART virally unsuppressed
Description
Proportion of HIV-positive children on ART with HIV RNA >1000 copies/mL 18 months after enrollment into the study.
Time Frame
18 months after study enrollment.
Secondary Outcome Measure Information:
Title
Proportion HIV-positive children on ART virally suppressed (<1,000 copies/mL of HIV RNA) at 6 and 12 months after study enrollment
Description
Proportion of HIV-positive children on ART with viral suppression (defined as HIV RNA copies/mL below the level of assay detection) and HIV RNA >1000 copies/mL
Time Frame
6 and 12 months after study enrollment
Title
Factors associated with HIV viral suppression
Description
Individual and family factors associated with viral suppression.
Time Frame
18 months after study enrollment
Title
Loss to follow-up
Description
Loss to follow-up (not seen in clinical care >3 months)
Time Frame
18 months after study enrollment
Title
ART initiation
Description
ART initiation in HIV-positive children not on ART at study entry
Time Frame
18 months after study enrollment
Title
Acceptability of the FAM-CARE program based on individual interview responses
Description
Acceptability of the FAM-CARE program to caregivers and health care provider as measured from responses on individual interviews using a structured questionnaire
Time Frame
18 months after study enrollment

10. Eligibility

Sex
All
Maximum Age & Unit of Time
14 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: HIV-positive child aged <15 years receiving HIV care at the study facility. Exclusion Criteria: At least one family member residing in the household is also HIV-positive and is receiving services at the study facility
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Caspian Chouraya, MD
Organizational Affiliation
Elizabeth Glaser Pediatric AIDS Foundation
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Nobuble Mthethwa, MD
Organizational Affiliation
Ministry of Health, Swaziland
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Lynne Mofenson, MD
Organizational Affiliation
Elizabeth Glaser Pediatric AIDS Foundation
Official's Role
Principal Investigator
Facility Information:
Facility Name
Mbabane
City
Mbabane
Country
Swaziland

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
All collected IPDs
IPD Sharing Time Frame
Six months after study publication
IPD Sharing Access Criteria
Datasets will be available for download upon request from Population Council/USAID website
Citations:
PubMed Identifier
34428241
Citation
Ashburn K, Chouraya C, Khumalo P, Mpango L, Mthethwa N, Machekano R, Guay L, Mofenson LM. A randomized controlled trial evaluating the effects of a family-centered HIV care model on viral suppression and retention in care of HIV-positive children in Eswatini. PLoS One. 2021 Aug 24;16(8):e0256256. doi: 10.1371/journal.pone.0256256. eCollection 2021.
Results Reference
derived

Learn more about this trial

Family-centered HIV Care, Viral Suppression and Retention in HIV-positive Children, Swaziland

We'll reach out to this number within 24 hrs